Even in patients who underwent postmastectomy radiotherapy (PMRT), as studied previously [27], OS benefits from RT were observed solely among those with hormone receptor-positive and HER2-negative breast cancers (including two HR+subtypes) [27]. Here, ERBB2 is linked to breast carcinoma.